SPTX — Seaport Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2042347 ·
Last close
$17.44
Market Cap
$933.57M
52W High
$23.00
52W Low
$14.85
ADV30
278,540
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,543,000 | -25,408,000 | 227,673,000 | 52,909,000 | 343,294,000 |
| Mar 2025 | 0 | — | -16,185,000 | -13,125,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-40,377,000
Investing CF
$-197,701,000
Financing CF
$-783,000
CapEx
$-54,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-06-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-139,517,000
Inventory
—
Receivables
$3,277,000
ST Investments
$129,696,000
EBIT TTM
$-43,728,000
Pretax Income TTM
$-37,983,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -87,294,000 | -74,881,000 | 249,009,000 | 341,554,000 | — | -77,942,000 |
| Dec 2024 | 0 | -52,416,000 | -46,879,000 | 315,777,000 | 340,626,000 | — | -29,629,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SDGR | Schrodinger, Inc. | $957.13M | $14.60 | — |
| XNCR | Xencor Inc | $905.27M | $12.21 | — |
| PHAR | Pharming Group N.V. | $905.06M | $12.81 | — |
| PCRX | Pacira BioSciences, Inc. | $894.77M | $22.74 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $974.17M | $9.81 | — |
News headlines (Yahoo Finance, 1h cache)
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
2026-06-09 06:00 · Yahoo
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-06-08 11:05 · Yahoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
2026-06-08 11:00 · Yahoo
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
2026-06-01 11:00 · Yahoo
Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price Move
2026-05-04 07:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.